Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice
- 14 May 2013
- journal article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 13 (9) , 1225-1228
Abstract
Objective: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. Methods: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. Results: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. Conclusions: Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life.Keywords
This publication has 12 references indexed in Scilit:
- Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticariaAnnals of Allergy, Asthma & Immunology, 2013
- Effects of Omalizumab Treatment in Patients With Refractory Chronic UrticariaAllergy, Asthma & Immunology Research, 2012
- Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide PerspectiveWorld Allergy Organization Journal, 2012
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseJournal of Allergy and Clinical Immunology, 2011
- Omalizumab is effective in nonautoimmune urticariaJournal of Allergy and Clinical Immunology, 2011
- Maintenance of Remission With Low-Dose Omalizumab in Long-Lasting, Refractory Chronic UrticariaAnnals of Allergy, Asthma & Immunology, 2010
- EAACI/GA²LEN/EDF/WAO guideline: management of urticariaAllergy, 2009
- Treatment of chronic autoimmune urticaria with omalizumabJournal of Allergy and Clinical Immunology, 2008
- Effect of omalizumab on patients with chronic urticariaAnnals of Allergy, Asthma & Immunology, 2007